ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression.
ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression.
复制标题
DOI：
10.3389/fnmol.2016.00169
复制
发表时间：
2016
影响因子：
4.8
通讯作者：
Burnet PW
中科院分区：
文献类型：
--
作者：
Chan SY;Matthews E;Burnet PW
自从发现单剂氯胺酮，N-甲基-D-天冬氨酸受体（NMDAR）拮抗剂具有迅速而持久的抗抑郁作用，因此对使用NMDAR调节剂的兴趣增加了，在抑郁症的药物疗法中似乎暗示着抑郁症的作用。讨论挑战这个观念。 Furthermore, NMDAR co-agonists have also been gaining attention as possible treatments. Co-agonists such as D-serine and sarcosine have shown effectiveness in both pre-clinical models and human trials. This raises the question of how both NMDAR antagonists and agonists are able to have converging behavioral effects. Here we critically review the evidence and proposed therapeutic mechanisms for both NMDAR antagonists and agonists, and collate several theories关于NMDAR的激活和抑制作用似乎都具有抗抑郁作用。
Since the discovery that a single dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, had rapid and long-lasting antidepressant effects, there has been increased interest in using NMDAR modulators in the pharmacotherapy of depression. Ketamine’s efficacy seems to imply that depression is a disorder of NMDAR hyperfunctionality. However, studies showing that not all NMDAR antagonists are able to act as antidepressants challenge this notion. Furthermore, NMDAR co-agonists have also been gaining attention as possible treatments. Co-agonists such as D-serine and sarcosine have shown efficacy in both pre-clinical models and human trials. This raises the question of how both NMDAR antagonists and agonists are able to have converging behavioral effects. Here we critically review the evidence and proposed therapeutic mechanisms for both NMDAR antagonists and agonists, and collate several theories on how both activation and inhibition of NMDARs appear to have antidepressant effects.